Kirsten rat sarcoma (KRAS) mutations (KRASms) are the most frequent lung cancer oncogenic mutations (25% of NSCLC and 30%–37% of adenocarcinoma cases), with the majority of cases involving codons 12 and 13 (4). This evidence concerns the gene KRAS and lung cancer.